National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Gardasil



Previous:pyrimethamine, pyroxamide, pyruvate kinase inhibitor TLN-232, QS21, Quadramet
Next:quarfloxacin, quinacrine dihydrochloride, Quinamed, quinidine, quinine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov